HC Wainwright Has Lowered Expectations for COMPASS Pathways (NASDAQ:CMPS) Stock Price

COMPASS Pathways (NASDAQ:CMPS) had its price objective decreased by HC Wainwright from $60.00 to $45.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright also issued estimates for COMPASS Pathways’ FY2028 earnings at $0.14 EPS and FY2029 earnings at $1.63 EPS.

A number of other research firms have also recently weighed in on CMPS. Maxim Group dropped their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and set a $18.00 price target on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $30.60.

COMPASS Pathways Stock Up 3.4 %

CMPS opened at $4.57 on Thursday. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The stock has a market cap of $312.68 million, a price-to-earnings ratio of -2.08 and a beta of 2.28. COMPASS Pathways has a twelve month low of $3.16 and a twelve month high of $12.75. The company’s 50-day moving average price is $4.10 and its two-hundred day moving average price is $5.49.

Institutional Trading of COMPASS Pathways

A number of institutional investors have recently modified their holdings of CMPS. Hennion & Walsh Asset Management Inc. lifted its stake in shares of COMPASS Pathways by 34.7% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 148,134 shares of the company’s stock valued at $933,000 after buying an additional 38,145 shares in the last quarter. Rosalind Advisors Inc. increased its holdings in COMPASS Pathways by 6.5% during the 3rd quarter. Rosalind Advisors Inc. now owns 781,423 shares of the company’s stock worth $4,923,000 after acquiring an additional 47,423 shares during the period. Propel Bio Management LLC bought a new stake in COMPASS Pathways during the 3rd quarter worth approximately $504,000. Acuta Capital Partners LLC bought a new stake in COMPASS Pathways during the 3rd quarter worth approximately $2,435,000. Finally, Walleye Capital LLC bought a new stake in COMPASS Pathways during the 3rd quarter worth approximately $2,126,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.